Y-mabs Therapeutics Stock Predictions

Healthcare > Biotechnology

Buy YMAB

*Your capital is at risk

$8.61

+0 (+0%)

At Close: Dec 15, 2025

Currently predicting for Mon, 8 Jun 2026

YMAB Prediction Chart

YMAB Predictions History

Latest community submissions for YMAB.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
JS Pro	Oct 31, 2022	$9.19 +2.91%	$3.61	X	0.00%	0
PredictionBot.Kathy Pro	Oct 31, 2022	$9.58 +7.26%	$3.61	X	0.00%	0
PredictionBot.Warren Pro	Oct 31, 2022	$13.53 +51.54%	$3.61	X	0.00%	0
jdevney2010	Oct 31, 2022	Bearish	$3.61	V	—	1
JS Pro	Feb 25, 2021	$37.91 +12.56%	$33.68	X	87.44%	0
Kevin Ripper @KevinRipper.214730	Feb 25, 2021	$37.00 +9.86%	$33.68	X	90.14%	0

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for YMAB with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT Y-MABS THERAPEUTICS INC.

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developin...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
LITE $905.00	4.43%	Jun 01
N NVRI $19.53	0.87%	May 20
RUN $12.83	15.51%	May 06
GLBE $31.61	4.05%	May 05
SAP $172.39	8.56%	May 05

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by